$9.03
5.05% yesterday
Nasdaq, Apr 03, 09:50 pm CET
ISIN
US09075A1088
Symbol
BVS

Bioventus Inc - Ordinary Shares - Class A Stock price

$9.15
-1.00 9.85% 1M
-2.52 21.59% 6M
-1.35 12.86% YTD
+4.13 82.27% 1Y
-4.14 31.15% 3Y
-3.85 29.62% 5Y
-3.85 29.62% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.36 3.79%
ISIN
US09075A1088
Symbol
BVS
Sector

Key metrics

Market capitalization $605.34m
Enterprise Value $957.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 26.15
EV/Sales (TTM) EV/Sales 1.67
P/S ratio (TTM) P/S ratio 1.06
P/B ratio (TTM) P/B ratio 4.07
Revenue growth (TTM) Revenue growth 11.89%
Revenue (TTM) Revenue $573.28m
EBIT (operating result TTM) EBIT $26.83m
Free Cash Flow (TTM) Free Cash Flow $36.61m
Cash position $41.58m
EPS (TTM) EPS $-0.52
P/E forward 25.90
P/S forward 1.07
EV/Sales forward 1.70
Short interest 1.77%
Show more

Is Bioventus Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bioventus Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

Buy
67%
Hold
33%

Financial data from Bioventus Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
573 573
12% 12%
100%
- Direct Costs 193 193
0% 0%
34%
381 381
19% 19%
66%
- Selling and Administrative Expenses 291 291
25% 25%
51%
- Research and Development Expense 14 14
1% 1%
2%
76 76
3% 3%
13%
- Depreciation and Amortization 50 50
14% 14%
9%
EBIT (Operating Income) EBIT 27 27
58% 58%
5%
Net Profit -34 -34
79% 79%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Bioventus Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioventus Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
24 days ago
Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to ...
Neutral
GlobeNewsWire
24 days ago
DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial guidance for full-year 2025.
Neutral
GlobeNewsWire
about one month ago
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same...
More Bioventus Inc - Ordinary Shares - Class A News

Company Profile

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Head office United States
CEO Robert Claypoole
Employees 930
Founded 2011
Website www.bioventus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today